Yourgene Health PLC Director's dealing (8441A)
03 June 2019 - 4:01PM
UK Regulatory
TIDMYGEN
RNS Number : 8441A
Yourgene Health PLC
03 June 2019
Yourgene Health plc
("Yourgene Health" or the "Company")
Director's Dealing
Manchester, UK - 3 June 2019: Yourgene Health (AIM: YGEN), the
international molecular diagnostics group which commercialises
genetic products and services, announces that it was notified on 31
May 2019 that Adam Reynolds, Chairman and a director of the
Company, purchased 900,000 ordinary shares of 0.10p each in the
Company on 31 May 2019 at a price of 11 pence per ordinary
share.
Following the purchase, Mr Reynolds holds 6,349,656 ordinary
shares in the Company representing 1.1% of the Company's issued
share capital.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Mr Adam Reynolds
----------------------------- ---------------------------------
2 Reason for the notification
----------------------------------------------------------------
a) Position/status Non-Executive Chairman / PDMR
----------------------------- ---------------------------------
b) Initial notification Initial
/Amendment
----------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------
a) Name Yourgene Health plc
----------------------------- ---------------------------------
b) LEI 213800UUIT8BZE7QEH33
----------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----------------------------------------------------------------
a) Description of the Ordinary shares of 0.10p each
financial instrument,
type of instrument
ISIN: GB00BN31ZD89
Identification code
----------------------------- ---------------------------------
b) Nature of the transaction Direct purchase of shares
----------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
11p 900,000
----------
----------------------------- ---------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
----------------------------- ---------------------------------
e) Date of the transaction 31 May 2019
----------------------------- ---------------------------------
f) Place of the transaction London Stock Exchange
----------------------------- ---------------------------------
For more information, please contact:
Yourgene Health plc Tel: +44 (0)161
Lyn Rees, Chief Executive Officer 667 1053
Barry Hextall, Chief Financial Officer
Joanne Cross, Head of Marketing
investors@yourgene-health.com
Cairn Financial Advisers LLP (Nomad) Tel: +44 (0)20 7213
Liam Murray / James Caithie / Ludovico Lazzaretti 0880
Stifel Nicolaus Europe Limited (Corporate Broker) Tel: +44 (0)20 7710
Nicholas Moore / Matthew Blawat / Ben Maddison 7600
Vigo Communications (PR) Tel: +44 (0)20 7390
Ben Simons / Fiona Henson / Antonia Pollock 0238
yourgene@vigocomms.com
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate
molecular diagnostic solutions, primarily for reproductive health.
The Group's products include non-invasive prenatal tests (NIPT) for
Down's Syndrome and other genetic disorders, Cystic Fibrosis
screening tests, invasive rapid aneuploidy tests, male infertility
tests and genetic disease tests. Yourgene's commercial footprint is
already established in the UK, Europe, the Middle East, Africa and
Asia.
Our product development, research service and commercial
capabilities extend across the lifecycle of genetic test
development including regulatory submissions. Through our technical
expertise and partnerships, Yourgene Health is also extending its
genetic testing offering into oncology.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei and Singapore, and is listed on the London Stock
Exchange's AIM market under the ticker "YGEN". For more information
visit www.yourgene-health.com and follow us on twitter
@Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHGMGGVRMLGLZG
(END) Dow Jones Newswires
June 03, 2019 02:01 ET (06:01 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024